{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:59:45Z","timestamp":1781643585871,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In an era of endemic SARS-CoV-2 transmission, countries are continuing to evaluate how best to schedule ongoing COVID-19 booster vaccinations. Mathematical modelling provides a useful tool to predict the benefit of future vaccination strategies, incorporating the loss of protection due to waning immunity and strain mutation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We adapted a combined immunological-population transmission model for SARS-CoV-2, to better capture contemporary understanding of exposure- and vaccine-derived immunity, to simulate ongoing endemic transmission of SARS-CoV-2 in a highly exposed high-income setting. We used this model to estimate the impact of targeted booster dose strategies in the older population, both in the context of continued circulation of the current dominant viral strain, and in the presence of a new antigenically distinct variant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found that at the population level, an annual COVID-19 vaccine booster dose to the 65+\u2009years population at 60% coverage could avert 8\u201316% of hospitalisations over a single wave, depending on how well-matched the vaccine is to the circulating SARS-CoV-2 strain. With lower coverage of 40%, estimated median impact was between 6% and 11%. A second booster dose to the 75+\u2009population after 6 months was particularly beneficial if a new distinct variant strain increases the magnitude of the wave. Of the vaccine scenarios explored, we found that increasing uptake of the annual booster dose in the 65+\u2009population is likely to have a larger impact on hospitalisations than optimising dose timing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This adapted model captures endemic viral transmission and could readily be used to explore vaccine impact across other settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-13074-3","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T08:05:47Z","timestamp":1774425947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Capturing SARS-CoV-2 immune landscapes to inform future strategies for COVID-19 vaccination in a high-income setting: a mathematical modelling study"],"prefix":"10.1186","volume":"26","author":[{"given":"Alexandra B.","family":"Hogan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Muscatello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bette","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Nedjati-Gilani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"13074_CR1","unstructured":"World Health Organization. WHO Director-General\u2019s opening remarks at the media briefing \u2013 5 May 2023 [Internet]. [cited 2024 Nov 22]. Available from: https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing---5-may-2023."},{"issue":"4","key":"13074_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJMoa2115481","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. N Engl J Med. 2022;386(4):340\u201350.","journal-title":"N Engl J Med"},{"key":"13074_CR3","unstructured":"World Health Organization. COVID-19 deaths | WHO COVID-19 dashboard [Internet]. [cited 2024 Dec 2]. Available from: https:\/\/data.who.int\/dashboards\/covid19\/cases"},{"key":"13074_CR4","unstructured":"Australian Government Department of Health and Aged Care. COVID-19 reporting [Internet]. Australian Government Department of Health and Aged Care; 2024 [cited 2024 Dec 2]. Available from: https:\/\/www.health.gov.au\/topics\/covid-19\/reporting."},{"key":"13074_CR5","unstructured":"Australian Bureau of Statistics (ABS). Deaths due to COVID-19, influenza and RSV in Australia\u2009\u2013\u20092022 - September 2024 | Australian Bureau of Statistics [Internet]. 2024 [cited 2024 Dec 3]. Available from: https:\/\/www.abs.gov.au\/articles\/deaths-due-covid-19-influenza-and-rsv-australia-2022-september-2024."},{"key":"#cr-split#-13074_CR6.1","unstructured":"Australian Government Department of Health and Aged Care. Australian Respiratory Surveillance Report 16-21 October 2024 to 17 November 2024 [Internet]. Australian Government Department of Health and Aged Care"},{"key":"#cr-split#-13074_CR6.2","unstructured":"2024 [cited 2024 Dec 3]. Available from: https:\/\/www.health.gov.au\/resources\/publications\/australian-respiratory-surveillance-report-16-21-october-2024-to-17-november-2024?language=en."},{"issue":"11","key":"13074_CR7","doi-asserted-by":"publisher","first-page":"e1004107","DOI":"10.1371\/journal.pmed.1004107","volume":"19","author":"I Bergeri","year":"2022","unstructured":"Bergeri I, Whelan MG, Ware H, Subissi L, Nardone A, Lewis HC, et al. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. PLOS Med. 2022;19(11):e1004107.","journal-title":"PLOS Med"},{"key":"13074_CR8","unstructured":"Kirby Institute. Serosurveillance for SARS-CoV-2 infection to inform public health responses [Internet]. [cited 2024 Dec 3]. Available from: https:\/\/www.kirby.unsw.edu.au\/research\/projects\/serosurveillance-sars-cov-2-infection-inform-public-health-responses."},{"key":"13074_CR9","unstructured":"UK Health Security Agency. GOV.UK. 2024 [cited 2024 Dec 3]. COVID-19 vaccine quarterly surveillance reports (September 2021 to November 2024). Available from: https:\/\/www.gov.uk\/government\/publications\/covid-19-vaccine-weekly-surveillance-reports."},{"key":"13074_CR10","doi-asserted-by":"crossref","unstructured":"Mccartney K, Liu B. Why older adults can continue to benefit from covid-19 boosters. BMJ. 2023;p1662.","DOI":"10.1136\/bmj.p1662"},{"key":"13074_CR11","unstructured":"World Health Organization. COVID-19 Vaccines Advice [Internet]. [cited 2024 Nov 22]. Available from: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/covid-19-vaccines\/advice."},{"key":"13074_CR12","unstructured":"Australian Government Department of Health and Aged Care. COVID-19 vaccine advice and recommendations [Internet]. Australian Government Department of Health and Aged Care; 2024 [cited 2024 Nov 22]. Available from: https:\/\/www.health.gov.au\/our-work\/covid-19-vaccines\/getting-your-vaccination"},{"key":"13074_CR13","unstructured":"World Health Organization. Statement on the antigen composition of COVID-19 vaccines [Internet]. [cited 2025 Feb 7]. Available from: https:\/\/www.who.int\/news\/item\/23-12-2024-statement-on-the-antigen-composition-of-covid-19-vaccines."},{"key":"13074_CR14","unstructured":"UK Health Security Agency. GOV.UK. [cited 2024 Dec 5]. National flu and COVID-19 surveillance report: 28 November (week 48). Available from: https:\/\/www.gov.uk\/government\/statistics\/national-flu-and-covid-19-surveillance-reports-2024-to-2025-season\/national-flu-and-covid-19-surveillance-report-28-november-week-48."},{"key":"13074_CR15","unstructured":"Australian Government Department of Health and Aged Care. COVID-19 vaccine rollout update \u2013 8 November 2024 [Internet]. Australian Government Department of Health and Aged Care; 2024 [cited 2024 Dec 5]. Available from: https:\/\/www.health.gov.au\/resources\/publications\/covid-19-vaccine-rollout-update-8-november-2024?language=en."},{"issue":"1829","key":"13074_CR16","doi-asserted-by":"publisher","first-page":"20210001","DOI":"10.1098\/rstb.2021.0001","volume":"376","author":"E Brooks-Pollock","year":"2021","unstructured":"Brooks-Pollock E, Danon L, Jombart T, Pellis L. Modelling that shaped the early COVID-19 pandemic response in the UK. Philos Trans R Soc B Biol Sci. 2021;376(1829):20210001.","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"13074_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.puhe.2024.07.029","volume":"236","author":"E Burch","year":"2024","unstructured":"Burch E, Khan SA, Stone J, Asgharzadeh A, Dawe J, Ward Z, et al. Early mathematical models of COVID-19 vaccination in high-income countries: a systematic review. Public Health. 2024;236:207\u201315.","journal-title":"Public Health"},{"issue":"1","key":"13074_CR18","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1038\/s41467-023-39736-3","volume":"14","author":"AB Hogan","year":"2023","unstructured":"Hogan AB, Doohan P, Wu SL, Mesa DO, Toor J, Watson OJ, et al. Estimating long-term vaccine effectiveness against SARS-CoV-2 variants: a model-based approach. Nat Commun. 2023;14(1):4325.","journal-title":"Nat Commun"},{"issue":"11","key":"13074_CR19","doi-asserted-by":"publisher","first-page":"e1004195","DOI":"10.1371\/journal.pmed.1004195","volume":"20","author":"AB Hogan","year":"2023","unstructured":"Hogan AB, Wu SL, Toor J, Mesa DO, Doohan P, Watson OJ, et al. Long-term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: A modelling study. PLOS Med. 2023;20(11):e1004195.","journal-title":"PLOS Med"},{"issue":"7","key":"13074_CR20","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205\u201311.","journal-title":"Nat Med"},{"key":"13074_CR21","doi-asserted-by":"crossref","unstructured":"Lo Tartaro D, Paolini A, Mattioli M, Swatler J, Neroni A, Borella R, et al. Detailed characterization of SARS-CoV-2-specific T and B cells after infection or heterologous vaccination. Front Immunol. 2023;14.","DOI":"10.3389\/fimmu.2023.1123724"},{"issue":"69","key":"13074_CR22","doi-asserted-by":"publisher","first-page":"eabo2202","DOI":"10.1126\/sciimmunol.abo2202","volume":"7","author":"CH GeurtsvanKessel","year":"2022","unstructured":"GeurtsvanKessel CH, Geers D, Schmitz KS, Mykytyn AZ, Lamers MM, Bogers S, et al. Divergent SARS-CoV-2 Omicron\u2013reactive T and B cell responses in COVID-19 vaccine recipients. Sci Immunol. 2022;7(69):eabo2202.","journal-title":"Sci Immunol"},{"key":"13074_CR23","unstructured":"Wu S, Watson OJ, Winskill P, Individual-Based. Model of COVID Transmission [Internet]. [cited 2025 Mar 4]. Available from: https:\/\/mrc-ide.github.io\/safir\/."},{"key":"13074_CR24","unstructured":"United Nations Population Division. World population prospects [Internet]. [cited 2024 Dec 12]. Available from: https:\/\/population.un.org\/wpp\/Download\/Standard\/MostUsed\/."},{"issue":"3","key":"13074_CR25","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1371\/journal.pmed.0050074","volume":"5","author":"J Mossong","year":"2008","unstructured":"Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 2008;5(3):e74.","journal-title":"PLoS Med"},{"issue":"22","key":"13074_CR26","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMc2211283","volume":"387","author":"M Canetti","year":"2022","unstructured":"Canetti M, Barda N, Gilboa M, Indenbaum V, Asraf K, Gonen T, et al. Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose. N Engl J Med. 2022;387(22):2092\u20134.","journal-title":"N Engl J Med"},{"issue":"1","key":"13074_CR27","doi-asserted-by":"publisher","first-page":"13417","DOI":"10.1038\/s41598-024-64414-9","volume":"14","author":"M Movsisyan","year":"2024","unstructured":"Movsisyan M, Truzyan N, Kasparova I, Chopikyan A, Sawaqed R, Bedross A, et al. Tracking the evolution of anti-SARS-CoV-2 antibodies and long-term humoral immunity within 2 years after COVID-19 infection. Sci Rep. 2024;14(1):13417.","journal-title":"Sci Rep"},{"issue":"3","key":"13074_CR28","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.immuni.2024.01.017","volume":"57","author":"K Srivastava","year":"2024","unstructured":"Srivastava K, Carre\u00f1o JM, Gleason C, Monahan B, Singh G, Abbad A, et al. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase. Immunity. 2024;57(3):587\u2013e5994.","journal-title":"Immunity"},{"issue":"6","key":"13074_CR29","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/evolut\/qpae041","volume":"78","author":"SP Otto","year":"2024","unstructured":"Otto SP, MacPherson A, Colijn C. Endemic does not mean constant as SARS-CoV-2 continues to evolve. Evolution. 2024;78(6):1092\u2013108.","journal-title":"Evolution"},{"key":"13074_CR30","unstructured":"UK Health Security Agency. GOV.UK. [cited 2024 Dec 12]. Winter Corona virus (COVID-19) infection study: estimates of infection hospitalisation and fatality risk, 30 May 2024. Available from: https:\/\/www.gov.uk\/government\/statistics\/winter-coronavirus-covid-19-infection-study-estimates-of-epidemiological-characteristics-england-and-scotland-2023-to-2024\/winter-coronavirus-covid-19-infection-study-estimates-of-infection-hospitalisation-and-fatality-risk-30-may-2024."},{"issue":"5","key":"13074_CR31","doi-asserted-by":"publisher","first-page":"106293","DOI":"10.1016\/j.jinf.2024.106293","volume":"89","author":"PD Kirwan","year":"2024","unstructured":"Kirwan PD, Foulkes S, Munro K, Sparkes D, Singh J, Henry A, et al. Protection of vaccine boosters and prior infection against mild\/asymptomatic and moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October 2023 to March 2024. J Infect. 2024;89(5):106293.","journal-title":"J Infect"},{"key":"13074_CR32","unstructured":"Australian Government Department of Health and Aged Care. COVID-19 Vaccine Rollout Update 10 January 2025 [Internet]. 2025. Available from: https:\/\/www.health.gov.au\/resources\/collections\/covid-19-vaccination-rollout-update."},{"key":"13074_CR33","unstructured":"Australian Government Department of Health and Aged Care. COVID-19 Vaccine Rollout Update 10 January 2024 [Internet]. 2024. Available from: https:\/\/www.health.gov.au\/resources\/collections\/covid-19-vaccination-rollout-update."},{"key":"13074_CR34","unstructured":"Australian Government Department of Health and Aged Care. COVID-19 vaccine rollout update 12 July 2024 [Internet]. 2024. Available from: https:\/\/www.health.gov.au\/resources\/publications\/covid-19-vaccine-rollout-update-12-july-2024?language=en."},{"key":"13074_CR35","doi-asserted-by":"publisher","first-page":"1412478","DOI":"10.3389\/fcimb.2024.1412478","volume":"14","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wei X, Liu Y, Li S, Pan W, Dai J, et al. Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines. Front Cell Infect Microbiol. 2024;14:1412478.","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"13074_CR36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/infdis\/jiae507","volume":"231","author":"D Dobrzynski","year":"2025","unstructured":"Dobrzynski D, Branche AR, Falsey AR. Combination Seasonal Vaccines for Influenza, Respiratory Syncytial Virus, Severe Acute Respiratory Syndrome Coronavirus 2, and Other Pathogens. J Infect Dis. 2025;231(2):291\u20133.","journal-title":"J Infect Dis"},{"issue":"9","key":"13074_CR37","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1038\/s41591-024-02949-0","volume":"30","author":"L Subissi","year":"2024","unstructured":"Subissi L, Otieno JR, Worp N, Attar Cohen H, Oude Munnink BB, Abu-Raddad LJ, et al. An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution. Nat Med. 2024;30(9):2400\u20133.","journal-title":"Nat Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13074-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13074-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13074-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:50:10Z","timestamp":1781643010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13074-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13074"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13074-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ABH has previously received funding from the World Health Organization (both paid to the institution and individually) for work relating to modelling pandemic-era COVID-19 vaccine impact. BL declares grants paid to their institution from the Australian National Health and Medical Research Council and Medical Research Future Fund.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"884"}}